Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.37 ^USD	+2.24%		+1.48%	+16.10%

Apr. 17	Sector Update: Health Care Stocks Retreating Late Afternoon	MT
Apr. 17	Sector Update: Health Care	MT

Connect Biopharma Holdings Limited Announces Resignation of Derek DiRocco as a Director

October 20, 2023 at 04:45 pm EDT

On October 18, 2023, Derek DiRocco, Ph.D. tendered his resignation as a director of Connect Biopharma Holdings Limited (the Company), effective October 18, 2023. Dr. DiRoccos resignation is not the result of any disagreement with the Company, including but not limited to, on any matter related to its operations, policies or practices.

Latest news about Connect Biopharma Holdings Limited

Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
HC Wainwright Adjusts Price Target on Connect Biopharma Holdings to $8 From $7, Maintains Buy Rating	Apr. 17	MT
Connect Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	Apr. 08	DJ
ADRs Advance; Connect Biopharma Climbs 19%	Apr. 05	DJ
ADRs Close Lower; Moatable Inc. Declines 33.3%	Apr. 04	DJ
ADRs End Higher; Connect Biopharma Climbs 26%	Apr. 01	DJ
ADRs End Higher; Connect Biopharma Holdings Climbs 21%	Mar. 27	DJ
HC Wainwright Starts Coverage on Connect Biopharma With Buy Rating, $7 Price Target	Mar. 04	MT
ADRs End Flat; Tuniu Climbs 16%	Feb. 23	DJ
Connect Biopharma Holdings Limited Appoints James Huang to Board of Directors	Feb. 12	CI
ADRs End With Gains; TC BioPharm Climbs 38%	Feb. 09	DJ
Transcript : Connect Biopharma Holdings Limited - Special Call	Dec. 12
Connect Biopharma Holdings Limited Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-To-Severe Persistent Asthma	Dec. 12	CI
Simcere Signs Commercialization Deal for Sale of Dermatitis Treatment in China	Nov. 22	MT
ADRs Slump, Connect Biopharma Holdings Ltd. Declines 38.8%	Nov. 21	DJ
Transcript : Connect Biopharma Holdings Limited - Special Call	Nov. 21
Simcere Pharmaceutical Group Limited Enters into an Exclusive License and Collaboration Agreement with Connect Biopharma Hongkong Limited in Relation to Rademikibart	Nov. 21	CI
Connect Biopharma Releases 'Positive' Stage 2 Atopic Dermatitis Trial Results; Unveils Licensing Deal; Shares Surge Premarket	Nov. 21	MT
Connect Biopharma Holdings Limited Appoints Kan Chen as Member of Compensation Committee	Nov. 21	CI
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-To-Severe Atopic Dermatitis	Nov. 21	CI
ADRs Advance; Trivago N.V. Climbs 86.6%	Nov. 02	DJ
ADRs Advance, Cellectis S.A. Climbs 172.2%	Nov. 01	DJ

Chart Connect Biopharma Holdings Limited

Duration

Period

Chart Connect Biopharma Holdings Limited

More charts

Company Profile

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Companyâs lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Companyâs third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). It has clinical development activities in the United States, the Peopleâs Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.

Sector

Biotechnology & Medical Research

Calendar

2024-09-09 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.34 USD

Average target price

7 USD

Spread / Average Target

+422.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CONNECT BIOPHARMA HOLDINGS LIMITED	+16.10%	73.84M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs